Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industry and ClavisBio signed a five-year drug collaboration agreement, according to a Friday filing with the Shanghai bourse.

The two companies will promote the preclinical development of the drugs.

ClavisBio will have the option to exclusively license the development, production, and commercialization of the products worldwide except in mainland China, Hong Kong, and Macau, where Fosun will have rights.

Should ClavisBio exercise its right to the projects, Fosun will be eligible for up to $362.5 million for a single project.

Fosun will also be entitled to royalties and a predetermined minority stake in a new project company set up by ClavisBio controlling shareholder AditumBioFund3 for the project, the filing said.

Shares in Fosun Pharma rose 3% in Shanghai and 2% in Hong Kong during late morning trading on Friday.